RT + XELOX group and mFOLFOX6 + CRT group significantly improved the near-term outcome (e.g., pCR rate) in patients with locally advanced rectal cancer with high-risk factors compared with CRT group. The RT + XELOX group also reduced the 3-year distant metastasis rate, increased the 3-year overall survival rate, and did not increase the incidence of perioperative surgical complications. It provides an effective means for the comprehensive treatment of locally advanced rectal cancer and has important clinical guidance and application value.
Keyphrases
- locally advanced
- rectal cancer
- phase ii study
- neoadjuvant chemotherapy
- risk factors
- squamous cell carcinoma
- radiation therapy
- patients undergoing
- randomized controlled trial
- lymph node
- clinical trial
- heart failure
- combination therapy
- left ventricular
- gestational age
- open label
- free survival
- replacement therapy
- metastatic colorectal cancer
- real time pcr